2267:TSEYakult Honsha Co., Ltd. Analysis
Data as of 2026-03-14 - not real-time
¥2,560.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Yakult trades at 2,560 JPY, just below its 20‑day SMA (2,606 JPY) but slightly above the 200‑day SMA (2,549 JPY), indicating a long‑term bullish bias. However, the MACD histogram is negative (‑9.4) and the line sits well under the signal, signaling short‑term momentum weakness. RSI at 46 is neutral, and the price sits near the identified support of 2,538 JPY with resistance around 2,749 JPY. Volume is increasing, and volatility over the past 30 days is high at ~21%, suggesting price swings.
Fundamentally, the stock carries a trailing PE of 17.9 and a forward PE of 14.5, modestly below the market average, while the price‑to‑book of 1.30 and dividend yield of 2.58% with a 45% payout ratio point to a sustainable income stream. The balance sheet is strong, with cash far exceeding debt, though the debt‑to‑equity ratio appears elevated at 15.7. Recent analyst commentary notes persistent domestic market headwinds that could pressure near‑term earnings, yet ongoing R&D in probiotics offers a longer‑term growth catalyst. Overall, the mix of defensive sector positioning, solid cash generation, and modest valuation suggests a cautious but optimistic outlook.
Fundamentally, the stock carries a trailing PE of 17.9 and a forward PE of 14.5, modestly below the market average, while the price‑to‑book of 1.30 and dividend yield of 2.58% with a 45% payout ratio point to a sustainable income stream. The balance sheet is strong, with cash far exceeding debt, though the debt‑to‑equity ratio appears elevated at 15.7. Recent analyst commentary notes persistent domestic market headwinds that could pressure near‑term earnings, yet ongoing R&D in probiotics offers a longer‑term growth catalyst. Overall, the mix of defensive sector positioning, solid cash generation, and modest valuation suggests a cautious but optimistic outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD histogram indicating short‑term momentum weakness
- Price near support level of 2,538 JPY
- Domestic earnings headwinds highlighted in recent analyst notes
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward PE of 14.5 suggesting upside potential
- Sustainable dividend yield of 2.58% with a 45% payout ratio
- R&D pipeline in probiotics offering growth beyond current market
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong cash position relative to debt
- Defensive consumer staples sector providing stability
- Global diversification mitigating domestic market slowdown
Key Metrics & Analysis
Financial Health
Revenue Growth-0.40%
Profit Margin8.97%
P/E Ratio17.9
ROE7.87%
ROA3.29%
Debt/Equity15.67
P/B Ratio1.3
Technical Analysis
TrendBullish
RSI46.1
Support¥2,538.00
Resistance¥2,748.50
MA 20¥2,606.38
MA 50¥2,565.12
MA 200¥2,548.58
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Target Price¥2,510.00
Upside/Downside-1.95%
GradeFair
TypeBlend
Dividend Yield2.58%
Risk Assessment
Beta-0.04
Volatility21.29%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.